Surmodics Company Profile (NASDAQ:SRDX)

About Surmodics (NASDAQ:SRDX)

Surmodics logoSurmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company's Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company's In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Adhesive
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:SRDX
  • CUSIP: 86887310
  • Web:
  • Market Cap: $393.93 million
  • Outstanding Shares: 13,109,000
Average Prices:
  • 50 Day Moving Avg: $26.12
  • 200 Day Moving Avg: $25.10
  • 52 Week Range: $21.90 - $30.75
  • Trailing P/E Ratio: 65.14
  • Foreward P/E Ratio: 130.65
  • P/E Growth: 8.90
Sales & Book Value:
  • Annual Revenue: $71.21 million
  • Price / Sales: 5.53
  • Book Value: $8.34 per share
  • Price / Book: 3.60
  • EBIDTA: $15.57 million
  • Net Margins: 8.66%
  • Return on Equity: 7.28%
  • Return on Assets: 6.01%
  • Current Ratio: 7.65%
  • Quick Ratio: 7.18%
  • Average Volume: 35,047 shs.
  • Beta: 0.85
  • Short Ratio: 13.54

Frequently Asked Questions for Surmodics (NASDAQ:SRDX)

What is Surmodics' stock symbol?

Surmodics trades on the NASDAQ under the ticker symbol "SRDX."

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) posted its earnings results on Thursday, August, 3rd. The company reported $0.09 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.01) by $0.10. The company earned $17.80 million during the quarter, compared to analyst estimates of $15.98 million. Surmodics had a net margin of 8.66% and a return on equity of 7.28%. Surmodics's revenue for the quarter was down 11.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.37 earnings per share. View Surmodics' Earnings History.

When will Surmodics make its next earnings announcement?

Surmodics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Surmodics.

What guidance has Surmodics issued on next quarter's earnings?

Surmodics updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $0.29-0.39 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.19. The company issued revenue guidance of $70.0-72.0, compared to the consensus revenue estimate of $67.59 million.

Where is Surmodics' stock going? Where will Surmodics' stock price be in 2017?

4 equities research analysts have issued 1 year target prices for Surmodics' shares. Their predictions range from $33.00 to $40.00. On average, they anticipate Surmodics' share price to reach $36.50 in the next twelve months. View Analyst Ratings for Surmodics.

Who are some of Surmodics' key competitors?

Who are Surmodics' key executives?

Surmodics' management team includes the folowing people:

  • Susan E. Knight, Independent Chairman of the Board
  • Gary R. Maharaj, President, Chief Executive Officer, Director
  • Andrew D. C. LaFrence, Vice President of Finance and Information Systems and Chief Financial Officer
  • Thomas A. Greaney, Executive Vice President of Medical Devices
  • Bryan K. Phillips, Senior Vice President - Legal and Human Resources, General Counsel & Secretary
  • Charles W. Olson, Senior Vice President of Commercial and Business Development, Medical Devices
  • Joseph J. Stich, Vice President, General Manager - In Vitro Diagnostics
  • Timothy J. Arens, Vice President - Corporate Development and Strategy
  • Gregg S. Sutton, Vice President - Research & Development
  • Lisa Wipperman Heine, Director

Who owns Surmodics stock?

Surmodics' stock is owned by many different of institutional and retail investors. Top institutional investors include Trigran Investments Inc. (9.48%), Renaissance Technologies LLC (7.57%), Vanguard Group Inc. (5.40%), Dimensional Fund Advisors LP (4.75%), Royce & Associates LP (2.81%) and State Street Corp (2.49%). Company insiders that own Surmodics stock include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Joseph J Stich, Susan E Knight and Timothy J Arens. View Institutional Ownership Trends for Surmodics.

Who sold Surmodics stock? Who is selling Surmodics stock?

Surmodics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Numeric Investors LLC, Acadian Asset Management LLC, Voya Investment Management LLC, Schwab Charles Investment Management Inc., Cornerstone Capital Management Holdings LLC., Eagle Global Advisors LLC and Spark Investment Management LLC. Company insiders that have sold Surmodics stock in the last year include Bryan K Phillips, Charles W Olson, Gary R Maharaj and Joseph J Stich. View Insider Buying and Selling for Surmodics.

Who bought Surmodics stock? Who is buying Surmodics stock?

Surmodics' stock was purchased by a variety of institutional investors in the last quarter, including Trigran Investments Inc., Dimensional Fund Advisors LP, Marshall Wace North America L.P., Vanguard Group Inc., PDT Partners LLC, Northern Trust Corp, Thrivent Financial For Lutherans and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Surmodics.

How do I buy Surmodics stock?

Shares of Surmodics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Surmodics' stock price today?

One share of Surmodics stock can currently be purchased for approximately $30.05.

MarketBeat Community Rating for Surmodics (NASDAQ SRDX)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about Surmodics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Surmodics (NASDAQ:SRDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $36.50 (21.46% upside)

Analysts' Ratings History for Surmodics (NASDAQ:SRDX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017Lake Street CapitalInitiated CoverageBuy -> Buy$40.00MediumView Rating Details
6/27/2017AegisInitiated CoverageBuyHighView Rating Details
11/21/2016Barrington ResearchDowngradeOutperform -> Market PerformN/AView Rating Details
10/6/2016SidotiDowngradeBuy -> Neutral$33.00N/AView Rating Details
(Data available from 9/19/2015 forward)


Earnings History for Surmodics (NASDAQ:SRDX)
Earnings by Quarter for Surmodics (NASDAQ:SRDX)
Earnings History by Quarter for Surmodics (NASDAQ SRDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017($0.01)N/AView Earnings Details
8/3/2017Q3 2017($0.01)$0.09$15.98 million$17.80 millionViewListenView Earnings Details
4/27/2017Q2 2017$0.07$0.05$16.21 million$17.50 millionViewN/AView Earnings Details
2/2/2017Q117$0.09$0.19$15.81 million$17.80 millionViewListenView Earnings Details
11/16/2016Q4 2016$0.09$0.26$16.09 million$18.20 millionViewListenView Earnings Details
7/28/2016Q316$0.12$0.37$16.31 million$19.97 millionViewListenView Earnings Details
5/2/2016Q2$0.09$0.20$14.71 million$16.70 millionViewListenView Earnings Details
1/28/2016Q116$0.17$0.38$14.58 million$16.50 millionViewListenView Earnings Details
11/10/2015Q415$0.19$0.30$15.30 million$17.40 millionViewListenView Earnings Details
8/5/2015Q315$0.21$0.26$14.86 million$15.90 millionViewListenView Earnings Details
4/30/2015Q2$0.20$0.19$14.09 million$14.40 millionViewListenView Earnings Details
1/29/2015Q414$0.21$0.25$14.30 million$14.20 millionViewListenView Earnings Details
11/6/2014Q314$0.25$0.26$14.90 million$15.30 millionViewN/AView Earnings Details
7/31/2014Q214$0.23$0.27$14.84 million$14.62 millionViewListenView Earnings Details
5/1/2014Q114$0.20$0.22$14.40 million$13.60 millionViewListenView Earnings Details
1/30/2014Q413$0.21$0.21$14.15 million$13.90 millionViewListenView Earnings Details
11/5/2013Q313$0.22$0.26$14.32 million$14.30 millionViewListenView Earnings Details
7/31/2013Q3 2013$0.21$0.22$15.03 million$14.29 millionViewListenView Earnings Details
5/7/2013Q2 2013$0.21$0.20$13.92 million$13.70 millionViewListenView Earnings Details
1/30/2013Q1 2013$0.18$0.29$13.63 million$13.85 millionViewListenView Earnings Details
11/6/2012Q412$0.17$0.17$13.83 million$13.80 millionViewN/AView Earnings Details
8/1/2012$0.14$0.17ViewN/AView Earnings Details
5/8/2012$0.15$0.14ViewN/AView Earnings Details
11/3/2011$0.05$0.06ViewN/AView Earnings Details
8/3/2011$0.04$0.13ViewN/AView Earnings Details
4/27/2011$0.08ViewN/AView Earnings Details
1/26/2011$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Surmodics (NASDAQ:SRDX)
2017 EPS Consensus Estimate: $0.18
2018 EPS Consensus Estimate: $0.20
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.05$0.12$0.09
Q2 20172$0.05$0.08$0.07
Q3 20172$0.00$0.03$0.02
Q4 20172($0.01)$0.04$0.02
Q1 20181$0.01$0.01$0.01
Q2 20181$0.06$0.06$0.06
Q3 20181$0.06$0.06$0.06
Q4 20181$0.07$0.07$0.07
(Data provided by Zacks Investment Research)


Dividend History for Surmodics (NASDAQ:SRDX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Surmodics (NASDAQ:SRDX)
Insider Ownership Percentage: 6.40%
Institutional Ownership Percentage: 84.85%
Insider Trades by Quarter for Surmodics (NASDAQ:SRDX)
Institutional Ownership by Quarter for Surmodics (NASDAQ:SRDX)
Insider Trades by Quarter for Surmodics (NASDAQ:SRDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Charles W OlsonVPSell801$27.85$22,307.85View SEC Filing  
9/11/2017Joseph J. StichVPSell1,000$27.28$27,280.00View SEC Filing  
8/7/2017Gary R MaharajCEOSell5,000$25.75$128,750.00View SEC Filing  
7/3/2017Gary R MaharajCEOSell5,000$28.03$140,150.00View SEC Filing  
6/16/2017Bryan K PhillipsSVPSell1,226$24.85$30,466.10View SEC Filing  
6/9/2017Joseph J StichVPSell1,000$25.31$25,310.00View SEC Filing  
6/5/2017Gary R MaharajCEOSell2,702$25.09$67,793.18View SEC Filing  
4/3/2017Gary R. MaharajCEOSell584$25.00$14,600.00View SEC Filing  
3/6/2017Joseph J. StichVPSell1,000$24.73$24,730.00View SEC Filing  
12/22/2016Charles W OlsonVPSell1,201$26.00$31,226.00View SEC Filing  
12/8/2016Charles W OlsonVPSell3,699$26.02$96,247.98View SEC Filing  
12/5/2016Joseph J StichVPSell1,000$23.97$23,970.00View SEC Filing  
12/2/2016Bryan K PhillipsSVPSell1,264$23.90$30,209.60View SEC Filing  
11/25/2016Charles W OlsonVPSell500$26.02$13,010.00View SEC Filing  
11/7/2016Gary R MaharajCEOSell5,000$25.22$126,100.00View SEC Filing  
10/3/2016Gary R. MaharajCEOSell5,000$29.55$147,750.00View SEC Filing  
8/17/2016Charles W OlsonVPSell9,936$28.98$287,945.28View SEC Filing  
8/15/2016Susan E. KnightDirectorSell1,548$28.64$44,334.72View SEC Filing  
8/1/2016Charles W OlsonVPSell12,500$27.08$338,500.00View SEC Filing  
6/14/2016Bryan K PhillipsSVPSell1,816$23.44$42,567.04View SEC Filing  
6/10/2016Joseph J StichVPSell1,000$23.33$23,330.00View SEC Filing  
5/27/2016Susan E KnightDirectorSell1,001$22.71$22,732.71View SEC Filing  
3/4/2016Timothy J ArensVPSell10,291$18.43$189,663.13View SEC Filing  
12/4/2015Joseph J StichVPSell1,000$21.18$21,180.00View SEC Filing  
9/4/2015Joseph J StichVPSell1,000$23.57$23,570.00View SEC Filing  
6/5/2015Joseph J StichVPSell1,000$23.84$23,840.00View SEC Filing  
5/22/2015Bryan K PhillipsSVPSell7,293$25.25$184,148.25View SEC Filing  
12/29/2014Charles W OlsonVPSell5,083$21.98$111,724.34View SEC Filing  
12/8/2014Charles W OlsonVPSell3,365$21.66$72,885.90View SEC Filing  
11/19/2014Timothy J ArensVPSell10,330$21.02$217,136.60View SEC Filing  
5/8/2014Susan KnightDirectorBuy1,500$20.36$30,540.00View SEC Filing  
12/4/2013Bryan PhillipsSVPSell16,236$22.95$372,616.20View SEC Filing  
5/15/2013Mark A LehmanInsiderSell1,693$26.55$44,949.15View SEC Filing  
8/10/2012Value Lp StarboardMajor ShareholderSell257,560$17.74$4,569,114.40View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Surmodics (NASDAQ:SRDX)
Latest Headlines for Surmodics (NASDAQ:SRDX)
DateHeadline logoSurmodics, Inc. (SRDX) VP Charles W. Olson Sells 801 Shares - September 19 at 8:32 PM logoSurmodics Announces Global Approvals Of .014" Low-Profile PTA Balloon Dilation Catheter - September 19 at 8:01 AM logoSurmodics Presents Encouraging SurVeil DCB Data at VIVA Meet - September 15 at 9:16 AM logoSix-Month Data from the Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2017 - September 14 at 10:40 AM logoInsider Selling: Surmodics, Inc. (SRDX) VP Sells 1,000 Shares of Stock - September 13 at 9:16 PM logoSurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : September 5, 2017 - September 6 at 8:36 AM logoSurmodics, Inc. (SRDX) Rating Increased to Hold at ValuEngine - September 2 at 1:50 PM logoSurmodics, Inc. (SRDX) Given Average Recommendation of "Hold" by Analysts - August 31 at 2:46 AM logoSurmodics, Inc. (SRDX) Stock Rating Upgraded by BidaskClub - August 28 at 6:50 PM logoSurModics, Inc. – Value Analysis (NASDAQ:SRDX) : August 15, 2017 - August 16 at 7:47 AM logoSurmodics, Inc. (SRDX) Downgraded by BidaskClub to "Sell" - August 12 at 11:32 PM logoInsider Selling: Surmodics, Inc. (SRDX) CEO Sells 5,000 Shares of Stock - August 9 at 9:06 PM logoQ4 2017 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Lowered by Barrington Research - August 7 at 8:02 AM logoSurmodics, Inc. (NASDAQ:SRDX) Given Average Rating of "Hold" by Analysts - August 6 at 7:10 AM logoSurmodics Reports Third Quarter Fiscal 2017 Results and Updates Fiscal 2017 Guidance - August 4 at 8:30 AM logoSurModics posts 3Q profit - August 4 at 8:30 AM logoEdited Transcript of SRDX earnings conference call or presentation 3-Aug-17 12:30pm GMT - August 4 at 8:30 AM logoSurmodics, Inc. (NASDAQ:SRDX) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS - August 3 at 8:52 PM logoSurmodics, Inc. (SRDX) Releases FY17 Earnings Guidance - August 3 at 9:26 AM logoSurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : August 2, 2017 - August 3 at 7:29 AM logoSurModics (SRDX) Announces Approval to Initiate Pivotal Trial of the SurVeil Drug-Coated Balloon - July 27 at 7:48 AM logoSurmodics to Webcast Third Quarter 2017 Earnings Conference Call on August 3 - July 26 at 8:13 AM logoSurmodics Receives IDE Approval to Initiate Pivotal Trial of the SurVeil™ Drug-Coated Balloon - July 26 at 8:13 AM logoSurmodics, Inc. (NASDAQ:SRDX) Set to Announce Earnings on Wednesday - July 19 at 9:14 AM logoFinancial Survey: Surmodics (SRDX) and H. B. Fuller Company (FUL) - July 15 at 10:08 AM logoSurmodics, Inc. (NASDAQ:SRDX) Coverage Initiated by Analysts at Lake Street Capital - July 14 at 9:48 AM logoCritical Review: H. B. Fuller Company (FUL) and Surmodics (NASDAQ:SRDX) - July 13 at 10:25 AM logoBidaskClub Lowers Surmodics, Inc. (NASDAQ:SRDX) to Buy - July 13 at 12:08 AM logoSurmodics, Inc. (SRDX) Given Consensus Rating of "Hold" by Brokerages - July 12 at 10:10 PM logoSurmodics (SRDX) vs. H. B. Fuller Company (FUL) Financial Analysis - July 2 at 10:28 PM logoH. B. Fuller Company (FUL) and Surmodics (SRDX) Financial Review - July 1 at 12:35 PM logoH. B. Fuller Company (FUL) vs. Surmodics (SRDX) Critical Comparison - June 30 at 12:22 AM logoZacks: Brokerages Set $33.00 Target Price for Surmodics, Inc. (SRDX) - June 28 at 10:30 AM logoSurmodics, Inc. (SRDX) Earns Buy Rating from Analysts at Aegis - June 27 at 8:06 AM logoHead to Head Comparison: Surmodics (SRDX) & H. B. Fuller Company (FUL) - June 22 at 12:26 PM logoSurmodics (SRDX) and H. B. Fuller Company (FUL) Critical Contrast - June 22 at 8:00 AM logoSurmodics, Inc. (SRDX) SVP Bryan K. Phillips Sells 1,226 Shares - June 20 at 7:50 PM logoFinancial Analysis: Surmodics (SRDX) & H. B. Fuller Company (FUL) - June 19 at 2:10 PM logoAnalyzing Meridian Bioscience (VIVO) & Surmodics (SRDX) - June 14 at 6:46 PM logoSurmodics, Inc. (SRDX) VP Sells $25,310.00 in Stock - June 13 at 8:40 PM logoFinancial Contrast: Oxford Immunotec Global PLC (OXFD) versus SurModics (SRDX) - June 10 at 2:46 PM logoInsider Selling: SurModics, Inc. (SRDX) CEO Sells 2,702 Shares of Stock - June 7 at 8:20 PM logoSurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : May 29, 2017 - May 29 at 6:49 PM logo SurModics, Inc. (SRDX) Receives Consensus Recommendation of "Hold" from Brokerages - May 29 at 4:36 PM logoSurmodics to Present at Upcoming Investor Conferences - May 22 at 8:51 AM logoETFs with exposure to SurModics, Inc. : May 5, 2017 - May 5 at 10:21 PM logoSurModics (SRDX) Given Daily Media Impact Score of 0.17 - May 3 at 9:24 PM logoSurModics, Inc. :SRDX-US: Earnings Analysis: Q2, 2017 By the Numbers : May 3, 2017 - May 3 at 6:10 PM logoSurModics, Inc. (SRDX) Downgraded by Zacks Investment Research - May 1 at 5:16 PM logoSurModics, Inc. to Post Q3 2017 Earnings of $0.00 Per Share, Barrington Research Forecasts (SRDX) - May 1 at 8:48 AM



Surmodics (SRDX) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by Staff